Back to results
US 2017/0254822 A1Published application
Methods and kits for detecting and diagnosing neurotrauma
OwnerRoger A. SABBADINIinventor
Life of this patent
Estimating the term…
Abstract
Methods and kits for detecting and diagnosing neurotrauma (e.g., traumatic brain injury, stroke, or spinal cord injury) are provided. These methods rely on the determination of lysophosphatidic acid (LPA) and/or LPA metabolite levels in patient samples following suspected injury.
Claims20
A method of detecting and treating neurotrauma, if present, in a human subject suspected of having sustained neurotrauma, comprising:
- (a) providing a biological sample of tissue or bodily fluid from a human subject suspected of having sustained neurotrauma within about the previous 36 hours;
- (b) using an anti-LPA antibody or LPA-binding antibody fragment to determine a level of a first biomarker that is lysophosphatidic acid (LPA) or an LPA metabolite in a biological sample of tissue or bodily fluid from said human subject by contacting the biological sample with the anti-LPA antibody or LPA-binding antibody fragment and detecting a level of binding between LPA and/or an LPA metabolite and the anti-LPA antibody or LPA-binding antibody fragment to determine the level of the first biomarker in the biological sample;
- (c) determining a level of said first biomarker that is LPA or an LPA metabolite in a negative control, wherein said determining is performed using an antibody- or antibody fragment-based method;
- (d) comparing said level of said first biomarker to the level of LPA or LPA metabolite in said negative control, wherein an elevated level of said first biomarker from said human subject compared to the negative control is indicative of the subject having sustained neurotrauma;
- and, if neurotrauma is present, and
- (e) reducing the effective concentration of LPA in the subject by administering to the subject an anti-LPA antibody or LPA-binding antibody fragment that reduces that effective concentration of LPA in the subject, thereby treating the subject for neurotrauma.
3 more elements
A kit for detecting neurotrauma in a human subject, wherein said kit comprises:
- an antibody- or antibody fragment-based means for determining a level of a first biomarker that is LPA or an LPA metabolite in a biological sample of tissue or bodily fluid from said human subject;
- instructions for using the kit, a negative control and an antibody- or antibody fragment-based means for determining a level of said first biomarker that is LPA or an LPA metabolite in said negative control, wherein an elevated level of LPA or an LPA metabolite compared to said negative control is indicative of neurotrauma.
Dependencies are inferred from the claim text.